Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus

Author:

Morel Chantal M.,Lindahl Olof,Harbarth Stephan,de Kraker Marlieke E. A.,Edwards Suzanne,Hollis Aidan

Abstract

AbstractThe scarcity of novel antibiotic compounds in a time of increasing resistance rates has begun to ring alarm bells at the highest echelons of government. Large new financial incentives to accelerate antibiotic research and development, such as market entry rewards (MERs), are being considered. However, there is little focus on how to sustain the efficacy of new, promising antibiotics reaching the market. Currently, inappropriate use of antibiotics is commonplace, which has accelerated resistance development. In an attempt to halt this trend, antibiotic stewardship policies are being implemented in many resource-rich settings. Unfortunately, this has not yet had an impact on the amount of antibiotics being prescribed globally. One important hurdle is misalignment of incentives. While governments and health services are incentivized to promote prudent use of this common good, pharmaceutical companies are incentivized to increase volume of sales to maximize profits. This problem must be addressed or else the major efforts going into developing new antibiotics will be in vain. In this paper we outline an approach to realign the incentives of pharmaceutical companies with wider antibiotic conservation efforts by making a staged bonus a component of an MER for antibiotic developers when resistance to their drug remains low over time. This bonus could address the lack of stewardship focus in any innovation-geared incentive.

Funder

Swiss National Fund

Vetenskapsrådet

Canadian Institute for Health Research

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology

Reference34 articles.

1. World Bank. Drug resistant infections: a threat to our economic future (vol. 2): final report. 2017. Report Number 114679. http://documents.worldbank.org/curated/en/323311493396993758/pdf/114679-REVISED-v2-Drug-Resistant-Infections-Final-Report.pdf.

2. UK Review on Antimicrobial Resistance. (chaired by Jim O’Neill). Tackling drug-resistant infections globally: final report and recommendations. 2016. https://amr-review.org/Publications.html.

3. Simpkin VL, Renwick MJ, Kelly R, Mossialos E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot. 2017;70:1087. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746591/#__ffn_sectitle.

4. Mossialos E, Morel CM, Edwards SE, Berensen J, Gemmill-Toyama M, Brogen D. Policies and incentives for promoting innovation in antibiotic research. European Observatory on Health Systems and Policies. 2010. http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf.

5. Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ. 2010;340:1115–8. http://www.bmj.com/bmj/section-pdf/186569?path=/bmj/340/7756/Analysis.full.pdf.

Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3